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Abstract
In recent years, the knowledge about bifidobacteria has considerably evolved thanks to recent progress in molecular biol-
ogy. The analysis of the whole genome sequences of 48 taxa of bifidobacteria offers new perspectives for their classifica-
tion, especially to set up limit between two species. Indeed, several species are presenting a high homology and should be
reclassified. On the other hand, some subspecies are presenting a low homology and should therefore be reclassified into
different species. In addition, a better knowledge of the genome of bifidobacteria allows a better understanding of the mech-
anisms involved in complex carbohydrate metabolism. The genome of some species of bifidobacteria from human but also
from animal origin demonstrates high presence in genes involved in the metabolism of complex oligosaccharides. Those
species should be further tested to confirm their potential to metabolize complex oligosaccharides in vitro and in vivo.
Key words: bifidobacteria, genomic, complex oligosaccharides, inuline, galacto oligosaccharides, human milk oligosac-
charide, bovine milk oligosaccharide
Introduction
In 1899, Tissier was the first person to isolate bifido-
bacteria from feces of breast-fed children. Because of
their “bifides” Y-shape, and because their physiology is
similar to lactobacilli, they have first been named Bacil-
lus bifidus and then classified in the genus Lactobacillus.
It was finally in 1974 with the 8th edition of Bergey’s
manual, that bifidobacteria were classified in a different
genus, the genus Bifidobacterium. This genus belongs to
the family of Bifidobacteriaceae, belonging to the order
of Bifidobacteriales and is one of the branches of the
phylum Actinobacteria. This phylum includes both
pathogens such as Mycobacterium spp. but also bacteria
beneficial to our health, such as bifidobacteria. The bacte-
ria included in this phylum have physiological and meta-
bolic properties as varied as their morphologies are
different. The genus Streptomyces is the most studied
taxon of this phylum as its metabolites have antibiotic
properties used in the pharmaceutical industry (Di Gioia
et al., 2014; Turroni et al., 2011; Turroni et al., 2014).
Bifidobacteria are Gram-positive saccharolytic bacteria
whose genome is rich in guanine and cytosine (G + C).
The vast majority of bifidobacteria are strict anaerobes,
but some of them are microaerophilic such as B. psy-
chraerophilum, B. crudilactis and B. mongoliense. They
present fermentation metabolism (De Vuyst et al., 2013;
Turroni et al., 2014) but they do not produce gas. They
are non-spore forming and non-motile bacteria (Bottacini
et al., 2014; Sela and Mills, 2010).
Bifidobacteria specifically degrade hexoses monosac-
charide (glucose and fructose) using the “fructose-6-
phosphate phosphoketolase pathway”, also called bifid
shunt. They are unable to classically ferment the hexoses
since they have neither the aldolase neither phosphofruc-
tokinase, (present in homo-fermentative lactic acid bacte-
ria) or glucose-6-phosphate dehydrogenase (present in
hetero-fermentative lactic acid bacteria). Therefore, they
are unable to ferment hexose monosaccharides through
the Emden-Meyerhof-Parnas (EMP) pathway or 6-phos-
phogluconate/phosphoketolase pathway, respectively.
However, with the bifid shunt and the production of a
specific enzyme: the fructose-6-phosphate phosphoketo-
lase (F6PPK), they are able to produce more ATP from
glucose and fructose. 
From the monosaccharides of two hexoses, there is a
formation of three moles of acetate, two moles lactate and
five moles of ATP. In theory, the acetate: lactate ratio is
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3:2. In reality, this ratio is rarely observed as pyruvate can
be metabolized in acetate, formate or even ethanol (De
Vuyst et al., 2013). If a large amount of carbohydrates is
available for the growth of bifidobacteria, a large amount
of lactate will be generated compared to acetate, formate
or ethanol. On the opposite, if the cell survival is threat-
ened, because the source of energy is less available, the
carbohydrates will be consumed slowly and lactate pro-
duction will be lower compared to a higher production of
acetate, formate and ethanol. This enables the bacteria to
produce and save more energy when a lot of substrate is
available. In the colon, the exogenous acetate produced
by bifidobacteria can be metabolised by butyrate-produc-
ing bacteria (De Vuyst et al., 2013). Therefore, the buty-
rogenic effect caused by butyrate-producing colon bac-
teria could rather be due to cross-feeding interactions
rather than direct fructan consumption. 
Bifidobacteria are also able to produce small amounts
of succinic acid, as demonstrated by Van der Meulen et
al. (2006) on 10 strains of bifidobacteria belonging to dif-
ferent species. This production seems to play a role in the
regeneration of NAD+ occurring through the production
of lactic acid or ethanol.
Excellent studies and literature reviews were recently
published about Bifidobacterium genus. The aim of this
review is to report those recent advances in molecular
biology and microbiology allowing new classification of
species inside the Bifidobacterium genus. In addition, an
update about the known metabolism involved in catabo-
lism of several complex oligosaccharides by those bacte-
ria is given.
Genotypic Characteristics and Taxonomy:
Focus on New Species
Our knowledge of bifidobacteria has considerably evol-
ved in recent years. Based on the current scientific know-
ledge, the genus Bifidobacterium consists today of 48 offi-
cial taxa representing 39 species and 9 subspecies (Lugli
et al., 2014). Forty taxa were isolated from the gastrointe-
stinal tract of mammals, birds, or insects (Arrieta et al.,
2014), and eight were isolated from sewage, fermented
milk or blood. As indicated by previous studies involved
in gastrointestinal microbiota analysis, additional bifido-
bacterial species are to be discovered in the future (Tur-
roni et al. 2012; Zoetendal et al., 2008) and further expan-
sion or refinement of the classification is to be expected.
Based on 16S rRNA sequences data from all recog-
nized species (1265 nucleotides), a tree highlighted 3 new
phylogenetic clusters groups, B. crudilactis, B. bohe-
micum and B. scardovii groups, in addition to the usual
six, representing: B. adolescentis, B. asteroides, B. boum,
B. longum, B. pullorum and B. pseudolongum (Lugli et
al., 2014; Turroni et al., 2014).
Based on 23S rRNA sequences, the analysis of the 48
taxa confirmed the classification into the six usual previ-
ously recognized groups.
However, the study of phylogeny within a specific
microbial taxon using only one molecular marker is lim-
ited today considering the tremendous progress in molec-
ular biology. In addition, 16S rRNA sequences can be of
high similarity for two different taxa. Several alternative
approaches were described using 16S rRNA gene associ-
ated with other genes. Analysis of identity levels based
on 16S rRNA and 23S rRNA sequences showed that 19
bifidobacterial pairs still present more than 97% of iden-
tify, the threshold usually considered for species separa-
tion (Lugli et al., 2014; Stackebrandt et al., 2002).  An
approach employing concatenation 16S rRNA gene with
six other housekeeping genes (clpC, dnaJ, xfp, dnaB,
rpoC and purF) for sequence analysis was described
(Ventura et al., 2006). This approach allowed a signifi-
cant increase of discrimination between taxa. Another ap-
proach according to Deletoile et al. (2010) based on con-
catenated sequences of the housekeeping genes clpC, fusA,
gyrB, ileS, purF, rplB and rpoB, and performed on 11
species allowed the classification of B. crudilactis and B.
mongoliense in two different clusters, well separated from
the other bifidobacteria clusters (Delcenserie et al., 2013).
Recent progress in molecular biology offer now the po-
ssibility to define an Average Nucleotide Identity (ANI)
using whole genome sequencing (Konstantinidis and Tie-
dje, 2005). The whole genome sequences of the 48 taxa
of bifidobacteria have been studied, and are, today, the
most complete genome analysis of those bacteria. They
allowed the identification of 18,435 bifidobacterium-spe-
cific clusters of orthologous genes (bifCOGs). Analysis
of these bifCOGs allowed the identification of 534 COGs
thereby forming the heart of the sequences encoding the
genome of bifidobacteria (core bifCOGs). With the sequ-
ences of the genomes, it was possible to identify a set of
411 genes that were then used to build a new phyloge-
netic tree for bifidobacteria, named “supertree”. That tree
highlighted 7 phylogenetic groups instead of the usual six,
with the appearance of a new cluster representing B. bifi-
dum group (Lugli et al., 2014). The ANI was also obtained
for each bifidobacterial pair and varied from 81.3% to
98.1% of identity. As suggested by Lugli et al. (2014),
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ANI could be used instead of DNA-DNA hybridization,
the gold standard, to set up the limit between two differ-
ent species. Interestingly, using ANI, the taxonomy of bi-
fidobacteria would be refined with the recognition of only
34 species of bifidobacteria instead of 39. Indeed, some
pairs presented a ANI of 97% such as B. stercoris, B.
coryneforme, B. kashiwanohense and B. saeculare com-
paring to respectively B. adolescentis, B. indicum, B. cat-
enulatum and B. gallinarum/B. pullorum). On the other
hand, the B. pseudolongum subsp. pseudolongum and B.
pseudolongum subsp. globosum pair presented an ANI
below 94% and should therefore be reclassified into two
different species. Other subspecies were confirmed with
ANI between 94 and 97% (Lugli et al., 2014).
The genome size of bifidobacteria chromosomes varies
from 1.9 to 2.8 Mbp. B. animalis has the smallest genome
and B. longum subsp. infantis has the largest. An average
of 2,012 open reading frames (ORFs) is observed per
genome. B. animalis subsp. lactis and B. longum subsp.
infantis are the species having the lowest and the most
ORF, respectively (Bottacini et al., 2014). The genome of
bifidobacteria adapts easily to new environments. Large-
scale commercial use has created new media very rich in
nutrients and, for example, B. animalis subsp. lactis has
adapted to these environments by losing genes. The
genome evolves over time through different mechanisms:
gene duplication, chromosomal rearrangements and DNA
vertical and horizontal intraspecies gene transfer (Botta-
cini et al., 2014).
The mobilome corresponds to all the mobile parts. It is
characterized by insertion sequences, bacteriophage ele-
ment, prophage-like elements or plasmides. The most
abundant and active insertion sequences are the IS30 ele-
ments. Those elements are responsible for deletions and
rearrangements into the genome and are involved in rapid
environmental adaptation of bifidobacteria, for example
an adaptation on a culture media (Lee and O’Sullivan,
2010).
Bacteriophages and prophage-like elements are
involved in lateral gene transfer. Apart from the strains of
B. longum subsp. longum and B. breve, bifidobacteria do
not contain plasmids (Bottacini et al., 2014).
Bifidobacteria are present in many ecological niches. It
is found in the human and animal intestinal tract (bovine,
rabbit, mice, chicken and insect), in the oral cavity, in
stagnant water and in food. As lactic acid bacteria, they
are often added to fermented foods, such as yoghurt.
However, the vast majority of bifidobacteria species is
only able to grow in the absence of oxygen, a condition
difficult to reproduce in industry. Some of them can sur-
vive the acidity of the stomach environment, duodenal,
bile salts and pancreatic juices but those are conditions
usually aggressive for bifidobacteria.
They are transmitted from mother to infant by direct
vertical transmission in most cases, but also indirectly by
contamination of the environment. Some bifidobacteria
have a cosmopolitan lifestyle (B. animalis, B. adolescen-
tis) while others are adapted to the digestive ecology of a
specific animal species. For example, B. cuniculi is en-
countered in rabbit, B. gallinarum in chicken and B.
pseudolongum in bovine (Turroni et al., 2011). Bifido-
bacteria adapted to a specific ecosystems can be excellent
indicators of fecal contamination and can be considered
as being more effective as currently used indicators such
as coliforms. For example, B. pseudolongum isolated from
raw milk cheese industry, indicates fecal contamination
of bovine origin and not from human origin because this
species is not encountered in the human intestinal tract
(Delcenserie et al., 2011). As mentioned earlier, the pre-
dominant species found in humans vary with age, and this
because of their genome. In a child, predominant species
are B. bifidum and B. longum subsp. infantis while in
adults it is B. adolescentis and B. longum subsp. longum.
Genes involved in carbohydrate metabolism are responsi-
ble for changing this distribution, in particular the genes
coding for carbohydrate transporters and for glycosidases,
mainly β-galactosidase and  β-fructofuranosidases (De
Vuyst et al., 2011). The majority of bifidobacteria enco-
untered in children have a genome oriented in the degra-
dation of human milk oligosaccharides (HMOs), while
those of adults have a genome oriented toward degrada-
tion of dietary carbohydrates. Degradation of complex car-
bohydrates, development of secondary metabolites and the
production of acetate and lactate through the Bifid Shunt
are based on interactions between bifidobacteria and other
microorganisms present in the intestinal tract (De Vuyst
et al., 2011). For example, Bacteroides and other gut bac-
teria secrete various glycosidases able to metabolize com-
plex sugars (Sela and Mills, 2010). Twelve percent of the
genome of bifidobacteria is dedicated to transportation of
carbohydrates or their metabolism, while 5% of the genome
is dedicated to protein metabolism (Sela and Mills, 2010).
Carbohydrate Fermentation Pattern
of Bifidobacteria
Inuline and fructooligosaccharides (FOS)
Inulin is composed of long chain of fructose. The deg-
4 Korean J. Food Sci. An., Vol. 35, No. 1 (2015)
ree of polymerisation (DP) of the inulin is 10 on average
but can range from 3 to 60. FOS are composed of the
same fructose found in inulin, but the degree of polymer-
ization range around 4 and can vary from 2 to 8. The
higher is the degree of polymerization, the longer the fer-
mentation will be. Thus the shortest OS will be consumed
first while the longest will be gradually consumed (Boss-
cher et al., 2006). Inulin is extracted from chicory roots
(Cichorium intybus) where it is present in more than 70%
in dry matter. Other foods naturally rich in inuline or FOS
include onions, artichokes, asparagus, leeks and cabbage
(Rossi et al., 2005). The oligofructose or FOS, are formed
by partial hydrolysis of inulin by fructanases and sucrases
(Chichlowski et al., 2011). They can also be produced by
transfructosylation from fructose. Inulin and FOS arrive
intact in the colon as they are neither absorbed nor
degraded due to their β bonds (1-2). The fermentation of
carbohydrates takes place in the proximal part of the
colon, which is highly saccharolytic comparing to the dis-
tal portion, which is more proteolytic. Fermentation of
inulin and FOS by lactobacilli and bifidobacteria pro-
duces organic acids such as lactate and succinate that can
exert antimicrobial effect against pathogenic bacteria by
reducing their growth, spread and passage into the blood-
stream, while promoting the growth of beneficial bacteria
and thus the defenses of host. In addition, thanks to its
high degree of polymerization, inulin is able to reach the
distal parts of the colon where it is preferentially proteol-
ysis, and is able to reduce the latter in favour of a more
beneficial saccharolytic activity (Bosscher et al., 2006).
Some strains of bifidobacteria are able to consume oli-
gofructose and inulin through a β-fructofuranosidase acti-
vity. Some strains are able to degrade small oligosaccha-
rides by intracellular degradation (Fig. 1(a)). This confers
a competitive advantage to those strains against inulin-
type fructan degraders such as lactobacilli, bacteroides
and roseburia. Some other strains are able to metabolize
long chain oligofructose and inulin. A recent study (Sti-
verson et al., 2014) demonstrated that a commercial for-
mulation of long chain inulin (Beneo® Synergy 1) exer-
ted a bifidogenic effect by increasing total bifidobacteria
and more specifically B. longum in infant microbiota. A
study performed with pig fecal microbiota showed that
long chain inulin increased total bifidobacteria (Han et
al., 2014). In this study, it was suggested that animal bifi-
dobacterial strains were better able to metabolize inulin
than human strains, especially long chain inulin (Average
DP of 25).
Fermentation of inulin and FOS produces short chain
fatty acid (SCFA), lactic acid and gas (carbon dioxide and
hydrogen). The produced SCFA such as acetate, propi-
onate and butyrate are either used by the intestinal micro-
biota, or used as an energy source by the host. Inulin and
FOS are able to provide 1.0 or 1.5 kcal/g, respectively
(Bossher et al, 2006). Inulin fermentation provide mainly
butyrate, while FOS provide preferentially acetate and
lactate. SCFA, especially butyrate, have an important role
in preventing colon cancer (Rossi et al., 2005). However,
as mentioned earlier, the production of butyrate is not due
to direct metabolism of inulin by bifidobacteria but rather
by cross-feeding interaction with butyrate-producing
colon bacteria, such as clostridia (De Vuyst et al., 2013).
Two types of cross-feeding have been identified, the first
concerns mono or oligosaccharides formed by bifidobac-
teria during degradation, while the second is the organic
acids such as lactate and acetate (De Vuyst and Leroy,
2011).
Galacto-oligosaccharides (GOS)
Galacto-oligosaccharides (GOS) are synthetized from
lactose and β-galactosidase. The main component of GOS
is 4’-galactosyl-lactose, which consists of one galactose
bonded to lactose through galactose β1-3/4/6 linkages.
The polymerization degree ranges from 3 to 15 and there
is a terminal glucose (Garrido et al., 2013). GOS are
widely used for their bifidogenic properties. However,
other species such as Bacteroides sp. and Clostridium sp.
are likely to metabolism GOS too.
In commercial formulations for infants, GOS are often
mixed with FOS. In previous described studies, the mix-
ture was composed of 90% GOS short chain and 10%
long chain FOS (inulin having DP> 23). With this ratio,
an increase in the number of bifidobacteria was observed
in infant feces. In parallel, a decrease in the incidence of
pathogens such as E. coli, Enterococcus and an improve-
ment of transit time and stool consistency was observed
(Chichlowski et al., 2011; Scholtens et al., 2014). A re-
cent study showed that GOS alone or in combination with
inulin were able to support the growth of B. longum and
to induce a strong antimicrobial effect against E. coli,
mainly due to the production of acetic acid (Stiverson et
al., 2014). A study performed with a gastrointestinal
model for pig demonstrated that B. thermophilum RBL67
was able to metabolize GOS and produce antimicrobial
effect against Salmonella Typhimurium through the pro-
duction of acetate (Tanner et al., 2014). Finally, another
study showed the potential of B. breve 46 to metabolize
GOS in a gastrointestinal model comparing to B.
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Fig. 1. A schematic representation of the degradations patterns of complex oligosaccharides by bifidobacteria.  Inspired from
Smilowitz et al., 2014, Garrido et al., 2012, Cardelle-Cobas et al., 2011, Zivkovic and Barile, 2011, Sela and Mills, 2010,
Boscher et al., 2006. (a) Degradation of FOS or inulin by bifidobacteria using a β-fructofuranosidase activity. Degrada-
tion of GOS by bifidobacteria using specific carriers and β-galactosidase activity. (b) Degradation of HMO by Bifidobac-
terium longum subsp. infantis using transport systems, intracellular glycosyl hydrolase and α-fucosidase, α-sialidase, β-
galactosidase and β-N-hexosaminidase. Degradation of HMO by Bifidobacterium bifidum using lacto-N-biosidase, α-
fucosidase, α-sialidase and LNB phosphorilase. Use of extracellular metabolized HMOs by B. breve and B. longum subsp.
longum. (c) Hypothetic degradation of BMO by bifidobacteria using mainly sialidase activity. Both potential pathways
involving either intracellular or extracellular degradation are represented. FOS, fructooligosaccharides; GOS, glucooligosaccha-
rides; HMO, human milk oligosaccharides; BMO, bovine milk oligosaccharides; LNB, lacto-N-biose; LNT: lacto-N-tetraose;
LNnT: lacto-N-neotetraose.
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pseudocatenulatum JCM1200 or B. animalis subsp. lactis
8:8 (Adamberg et al., 2014).
To degrade GOS, bifidobacteria should be able to syn-
thetize specific carriers and β-galactosidases (Fig. 1(a)).
For example, B. longum subsp. infantis has 5 genes en-
coding β-galactosidases, 3 of them being involved in me-
tabolism of GOS. It preferentially consumes GOS with a
polymerisation degree of 4, but all subspecies, due to
phenotypic differences, will not consume the same way
(Garrido et al., 2013). In addition, the degree of polymer-
ization and the connection types influence its degradation
and the speed of degradation too (Cardelle-Cobas et al.,
2011).
Human milk oligosaccharides (HMO) and bovine
milk oligosaccharides (BMO)
Human milk oligosaccharides (HMO)
The formation of HMO occurs in the mammary gland
with β-galactotransferase in the presence of α-lactalbu-
min. Glucose and galactose, linked by a β1-4 linkage form
the so-called lactose heart. HMOs are formed from 5
monosaccharides: glucose, galactose, N-acetylglucosa-
mine, fucose and sialic acid. They may be linear or
branched and include from 3 to 14 monosaccharides. The
terminal lactose can be linked to a fucose (through α-1,2,
α-1,3 or α-1,4 liaisons) or sialic acid (through α-2,3 or α-
2,6 liaisons). This terminal lactose can be elongated by a
lacto-N- biose type 1 or N- acetyllactosamine. In human
milk, a recent estimate fixed fucosylated HMO to 35 to
50%, sialylated to 12 to 14% HMO and 42 to 55% as
neutral nonfucosylated HMO. In the presence of nega-
tively charged sialic acid, HMO is qualified as acid. Oth-
erwise it is called neutral (Smilowitz et al., 2014).
HMO concentration reaches 25 g/L in colostrum and 10
to 15 g/L in mature milk. More than 200 different struc-
tures have been identified so far (Mehra et al., 2014).
Because of their bifidogenic properties, HMOs play an
active role in the development of a beneficial microbiota
in infant by allowing the growth of specific bacteria. In
addition, it is described that HMOs increase the immune
defenses of the host. One of the mechanism is that fuco-
sylated HMOs present similarity with surface receptors of
the mucous layer in the intestinal tract and therefore bind
to pathogens, allowing them to be washed out naturally
(Smilowitz et al., 2014). The sialylated HMOs are also
involved in brain and cognitive development of the child
(Wu et al., 2011). HMOs are protected from human dige-
stion through their terminal sialylated and fucosylated
chains. Therefore, bifidobacteria must have clusters of
genes encoding specific enzymes and carriers to be able
to digest these HMOs. It has been described that those
gene clusters are located on mobile parts (Sela, 2011). In
addition, there is a co-evolution between HMO present in
the microbiota and bifidobacteria able to use them (Ger-
man et al., 2008). More recently, it has been described that
some bifidobacteria clusters are more particularly adapted
for HMO catabolism (Milani et al., 2014). Indeed, that
cluster seems to have lost genes encoding glycosyl hydro-
lases involved in the degradation of plant polysaccha-
rides.
B. longum subsp. infantis preferentially metabolize
small HMO (degree of polymerization of less than 8 and
molecular weight of less than 1400 Da), which represent
64 % of the available HMO (Sela and Mills, 2010). It is
able to grow in a medium containing HMO as a sole car-
bon source. With its gene cluster of 43 kb which encodes
transport systems and intracellular glycosyl hydrolases,
B. infantis possesses genes coding for 4 enzymes neces-
sary for digestion of HMO: α-fucosidase , α-sialidase , β-
galactosidase and β-N-hexosaminidase. This bacterium
possesses as well genes of ABC transporters and their
associated specific binding proteins (SBP). B. infantis
internalizes the HMO and only then exposes the degraded
lactose heart deprived of its fucose or sialic acid (Sela et
al., 2008; Sela, 2011; Smilowitz et al., 2014).
On the opposite, the digestion of HMO by B. bifidum is
an extracellular process. The cluster of genes present in
B. infantis is absent from the genome of B. bifidum and
different enzymes are synthetized: lacto-N-biosidase in
addition to sialidase and fucosidases. These separate LNB
(lacto-N-biose) from HMO. It passes through the mem-
brane, with an ABC transporter associated with a specific
SBP, and is then degraded intracellularly (Sela, 2011;
Smilowitz et al., 2014). Interestingly, B. bifidum and B.
infantis grow relatively well in HMOs, but have distinct
clusters of genes involved in their metabolism (Barile and
Rastall, 2013). A schematic representation of the degra-
dations patterns is presented in Fig. 1(b).
Interestingly, unlike B. longum subsp. infantis that has
all the necessary genes to digest HMO and is conse-
quently highly represented in the microbiota of a breast-
fed child, B. longum subsp. longum (part of the majority
bifidobacteria microbiota in adult) is unable to metabolize
HMO (De Vuyst et al., 2013). However, there is a close
cooperation in the metabolism of HMO between different
bifidobacteria. B. longum subsp. longum, B. bifidum and
B. breve are able to metabolize lacto-N-biose obtained
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after HMO metabolism by B. infantis. LNB can be meta-
bolized through the action of fucosidases and lacto-N-
biosidases in an extracellular process. Monosaccharides
obtained from successive HMO degradations are mainly
used by B. breve (Barile and Rastall, 2013; Sela and
Mills, 2010).
Bovine milk oligosaccahrides (BMO)
The concentration of BMO in bovine colostrum range
from 0.7 to 1.2 g/L while the concentration of HMO in
human milk range from 20 to 23 g/L. More than 60 kinds
of BMO have already been identified (Pacheco et al.,
2014). The composition of sialylated BMO compounds
reaches 70%, whereas it is 20% for HMOs (Kelly et al.,
2013). They are constructed from a lactose heart, but can
also be constructed from a lactosamine heart that human
milk does not contain. Sialic acids are two in number: N-
acetylneuraminic  acid (NeuAc) and N-glycolylneuraminic
acid (NeuGc). Out of the 70% of sialylated BMO, 5%
contain NeuGc. Monomers of BMO are: glucose, galac-
tose (Gal), N-acetylglucosamine (GlcNAc), fucose (Fuc),
NeuAc and NeuGc. The NeuGc is not found in human
milk, HMOs being highly fucosylated (70%), while in
bovine milk, fucosilation is potentially possible but in
very small quantities. The amount of fucose is estimated
to be less than 0.01% (Tao et al., 2008).
BMO could represent an inexpensive and effective
source of prebiotic. Indeed, the cheese industry produce
whey in large quantities and whey is naturally rich in
BMO. The structure of BMO, because of its ramifica-
tions, is much closer to HMO than FOS or linear struc-
ture. As a result, profits on the host health may be imp-
roved (Mehra et al., 2014; Zivkovic et Barile, 2011). In
addition they enhance the growth of bifidobacteria, inhi-
bit the attachment of pathogens to the intestinal mucosa
and modulate immunity (Urashima et al., 2013).
The polymerization degree of BMOs is lower than that
of the HMOs, but the β-glycosidic bonds of galactose and
N- acetylglucosamine to lactose are similar. Those bonds,
like those of HMOs, protect BMO from human digestive
enzymes. Indeed, the host has only the ability to digest the
glycosidic bond of lactose. The fact that there are more
sialylated BMO (N-acetylneuraminic acid and N-lylneu-
raminic acid) probably affects the bioavailability of BMO
(Chichlowski et al., 2011). A hypothesis about the possi-
ble mechanisms comparing to HMO is presented in Fig.
1(c).
An interesting study from Meli and coll (2014) assessed
the use of a commercial infant formula supplemented with
BMOs instead of lactose. This is the first study reporting
the use of BMOs in infant formula. Two formulas were
tested: one containing BMOs (Formula 1) and another
one containing BMOs and the probiotics B. longum Bl999
and Lactobacillus rhamnosus LPR (Formula 2). Both for-
mulas were able to induce changes in infant microbiota
by increasing total number of bifidobacteria. No signifi-
cant difference were observed between Formula 1 or 2
suggesting that with the bifidobacteria concentrations used
in this study, the BMOs exerted a more influent effect on
total bifidobacteria counts. However, total lactobacilli
were not influenced by those formulas.
Conclusion
Recent progress in molecular biology allowed consider-
able evolution of the knowledge about bifidobacteria. The
study of phylogeny within a specific microbial taxon
using only one molecular marker is limited today consid-
ering the tremendous progress in molecular biology. Sev-
eral alternatives approaches were described using 16S
rRNA gene associated with several housekeeping genes.
Those approaches allowed a significant increase of dis-
crimination. Recent studies about bifidobacteria allowed
to obtain an Average Nucleotide Identity (ANI) using
whole genome sequencing of 48 taxa of bifidobacteria.
Using that method, the taxonomy of bifidobacteria could
be refined with the recognition of only 34 species of bifi-
dobacteria instead of 39. Indeed, some pairs presented a
ANI of 97% such as B. stercoris, B. coryneforme, B. ka-
shiwanohense and B. saeculare comparing to respectively
B. adolescentis, B. indicum, B. catenulatum and B. galli-
narum/B. pullorum). On the other hand, the B. pseudolon-
gum subsp. pseudolongum and B. pseudolongum subsp.
globosum pair presented an ANI below 94% and should
therefore be reclassified into two different species.
In addition, a better knowledge of the genome of bifi-
dobacteria allows a better understanding of the mecha-
nisms involved in complex carbohydrate metabolism. For
example, a co-evolution between HMO present in the mi-
crobiota and bifidobacteria able to use them can be iden-
tified in the genome. Some bifidobacteria clusters are more
particularly adapted for HMO catabolism and that cluster
seems to have lost genes encoding glycosyl hydrolases
involved in the degradation of plant polysaccharides.
The metabolism of complex sugars such as inuline,
fructo-oligosaccharides, galacto-oligosaccharides, human
milk oligosaccharides and bovine milk oligosaccharides
is well known for several species such as B. longum subsp.
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infantis, B. bifidum and B. breve. The genome of other
species of bifidobacteria originated from human and ani-
mal demonstrates a remarkable enrichment in genes invol-
ved in the metabolism of a wide variety of complex poly-
saccharides. Those species should be further tested to con-
firm their potential to metabolize complex oligosaccha-
rides in vitro and in vivo.
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